CLEVELAND, July 18, 2019 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today details relating to the release of
its second quarter 2019 financial results.
ViewRay will hold a conference call to discuss results on
Thursday, August 8, 2019 at
4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844)
277-1426 for domestic callers and (336) 525-7129 for
international callers. The conference ID number is 1695303.
A live webcast of the conference call will be available on the
investor relations page of ViewRay's corporate website at
www.viewray.com.
After the live webcast, a replay of the webcast will remain
available online on the investor relations page of ViewRay's
corporate website, www.viewray.com, for 14 days following the call.
In addition, a telephonic replay of the call will be available
until August 15, 2019. The replay
dial-in numbers are (855) 859-2056 for domestic callers and (404)
537-3406 for international callers. Please use the conference ID
number 1695303.
About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets
the MRIdian® radiation therapy system. MRIdian is built
upon a proprietary high-definition MR imaging system designed from
the ground up to address the unique challenges and clinical
workflow for advanced radiation oncology. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was purpose
built to address specific challenges, including beam distortion,
skin toxicity, and other concerns that potentially may arise when
high magnetic fields interact with radiation beams. ViewRay and
MRIdian are registered trademarks of ViewRay, Inc.
Forward Looking Statements:
This press release contains forward-looking statements within
the meaning of Section 27A of the Private Securities Litigation
Reform Act. Statements in this press release that are not purely
historical are forward-looking statements. Such forward-looking
statements include, among other things, the rate of new orders,
upgrades and installations, ViewRay's financial guidance for the
full year 2019 and ViewRay's conference call to discuss its first
quarter results. Actual results could differ from those projected
in any forward-looking statements due to numerous factors. Such
factors include, among others, the ability to commercialize MRIdian
Linac System, demand for ViewRay's products, the ability to convert
backlog into revenue, and the timing of delivery of ViewRay's
products, the timing, results and other uncertainties associated
with clinical trials, the ability to raise the additional funding
needed to continue to pursue ViewRay's business and product
development plans, the inherent uncertainties associated with
developing new products or technologies, competition in the
industry in which ViewRay operates and overall market conditions.
For a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to ViewRay's
business in general, see ViewRay's current and future reports filed
with the Securities and Exchange Commission, including its Annual
Report on Form 10-K for the fiscal year ended December 31, 2018 and its Quarterly Report on
Form 10-Q for the fiscal quarter ended March
31, 2019, as updated periodically by the company's other
filings with the SEC. These forward-looking statements are made as
of the date of this press release, and ViewRay assumes no
obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those projected in
the forward-looking statements, except as required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viewray-announces-conference-call-and-webcast-of-second-quarter-2019-financial-results-to-be-held-after-market-on-august-8-2019-300885585.html
SOURCE ViewRay, Inc.